Status:
COMPLETED
Identification of Immunomodulators Associated With Atrial Fibrillation Reporting: Analysis of the WHO Pharmacovigilance Database
Lead Sponsor:
University Hospital, Caen
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
Brief Summary
Atrial fibrillation is the most prevalent sustained arrhythmia worldwide with a great morbimortality. Some populations are more at risk to develop atrial fibrillation like patients suffering from infl...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Case reported in the World Health Organization (WHO) database of individual safety case reports to 01/09/2022
- Patients treated with FDA approved immunomodulators (approval the 1st January 2023).
Exclusion
Key Trial Info
Start Date :
August 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2022
Estimated Enrollment :
4000000 Patients enrolled
Trial Details
Trial ID
NCT06095791
Start Date
August 1 2022
End Date
September 1 2022
Last Update
October 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alexandre Joachim
Caen, Basse Normandie, France, 14000